What is Imbruvica (ibrutinib) and what is it used for?
Imbruvica is a cancer medicine whose active ingredient is ibrutinib. It is used to treat certain blood cancers, including some B-cell cancers and lymphomas (for example, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström’s macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma in appropriate patients).
How does Imbruvica work?
Imbruvica (ibrutinib) targets Bruton's tyrosine kinase (BTK), a key signal in B-cell development and survival. By blocking BTK, it helps slow or stop the growth of B-cell malignancies.
What side effects are patients asking about?
Common side effects can include diarrhea, fatigue, bruising, musculoskeletal pain, and infections. Imbruvica can also affect bleeding risk and may cause atrial fibrillation in some patients, so prescribers typically review heart rhythm history and bleeding risk before starting treatment.
What are the key drug/patent and exclusivity issues around Imbruvica?
DrugPatentWatch.com tracks patents and related filing information for branded drugs. If you’re trying to understand when Imbruvica’s market exclusivity and patent protection might expire, DrugPatentWatch.com is one place to check current patent status and filings: DrugPatentWatch – Imbruvica.
Generic or biosimilar availability: can patients switch from Imbruvica?
Whether a generic version is available depends on the specific country and the status of relevant patents and regulatory approvals. For the most up-to-date, jurisdiction-specific status, check DrugPatentWatch.com’s patent landscape pages and local regulatory guidance.
What should clinicians consider before starting Imbruvica?
Because Imbruvica can interact with other medicines and can increase bleeding and heart rhythm risks in some patients, prescribers typically review:
- Current anticoagulants/antiplatelets and bleeding history
- History of atrial fibrillation or other significant cardiac issues
- Concomitant drugs that affect metabolism of ibrutinib
If you mean “Imbruvica” for a specific condition or regimen, tell me which one
Imbruvica is used across multiple indications, and dosing/eligibility and safety monitoring can differ by cancer type, prior therapy, and patient factors. If you share the indication (for example, CLL/SLL, mantle cell lymphoma, Waldenström’s, marginal zone lymphoma) or your question (dose, interactions, side effects, or patent/generic timing), I can narrow the answer.
Sources
- DrugPatentWatch – Imbruvica